In This Article:
Over the last 7 days, the Indian stock market has dropped 1.0%, although it is up 39% over the past year with earnings forecasted to grow by 17% annually. In this dynamic environment, identifying stocks with strong fundamentals and growth potential can be key to uncovering hidden gems that may offer substantial returns.
Top 10 Undiscovered Gems With Strong Fundamentals In India
| Name | Debt To Equity | Revenue Growth | Earnings Growth | Health Rating |
|---|---|---|---|---|
| Bengal & Assam | 4.48% | 1.53% | 51.11% | ★★★★★★ |
| Wealth First Portfolio Managers | NA | -47.95% | 40.47% | ★★★★★★ |
| Force Motors | 23.24% | 21.52% | 44.24% | ★★★★★☆ |
| Indo Amines | 82.32% | 17.15% | 19.98% | ★★★★★☆ |
| Master Trust | 37.05% | 27.64% | 41.99% | ★★★★★☆ |
| Kaycee Industries | 17.35% | 19.50% | 34.62% | ★★★★★☆ |
| Lotus Chocolate | 13.51% | 28.07% | -10.66% | ★★★★★☆ |
| KP Green Engineering | 13.73% | 47.60% | 61.28% | ★★★★★☆ |
| Magadh Sugar & Energy | 85.44% | 6.65% | 13.60% | ★★★★☆☆ |
| Vasa Denticity | 0.11% | 38.37% | 48.77% | ★★★★☆☆ |
Here we highlight a subset of our preferred stocks from the screener.
Kaveri Seed
Simply Wall St Value Rating: ★★★★★★
Overview: Kaveri Seed Company Limited researches, develops, produces, processes, and markets hybrid seeds and vegetable crop seeds in India with a market cap of ₹59.87 billion.
Operations: Kaveri Seed generates revenue primarily from the sale of hybrid seeds and vegetable crop seeds. The company has a market cap of ₹59.87 billion.
Kaveri Seed, a small cap player in India's agricultural sector, reported robust earnings for Q1 2024 with sales reaching ₹8.03 billion (previously ₹7.36 billion) and net income at ₹2.89 billion (up from ₹2.74 billion). The company repurchased shares this year and has reduced its debt-to-equity ratio from 0.7 to 0.01 over five years, reflecting strong financial management. Despite recent executive changes, Kaveri Seed remains well-positioned with an EBIT interest coverage of 1038x and forecasted earnings growth of 8.23% annually.
Marksans Pharma
Simply Wall St Value Rating: ★★★★★★
Overview: Marksans Pharma Limited, along with its subsidiaries, focuses on the research, manufacturing, marketing, and sale of pharmaceutical formulations across various international markets including the United States, North America, Europe, the United Kingdom, Australia, and New Zealand with a market cap of ₹117.08 billion.
Operations: Marksans Pharma generates revenue primarily from the sale of pharmaceutical formulations, amounting to ₹22.68 billion. The company has a market cap of ₹117.08 billion.